- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Placebo, TSND-201
- Drug
- Lead sponsor
- Transcend Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more
Location Directory
Clinical trials in Seattle, Washington
This page shows live ClinicalTrials.gov search results for Seattle, Washington, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
5123
Shown on this page
12
Local exact-city summaries
5123
Based on exact city/state matches in the local index.
Local exact-city recruiting
959
Live official results below use the broader ClinicalTrials.gov location search.
Showing 1–12 of 5,123 matching trials in Seattle, WA.
Indexed local directory records.
Top conditions in local exact-city summaries
Top sponsors in local exact-city summaries
Top therapies in local exact-city summaries
Indexed official records
Open in full search- Conditions
- Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 187
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 149 more
- Conditions
- Endometrial Cancer, Malignant Solid Tumour
- Interventions
- Doxorubicin, Paclitaxel, Puxitatug Samrotecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 66
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 57 more
- Conditions
- Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- placebo, ponsegromab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 982 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Bryant, Arkansas • Conway, Arkansas + 27 more
- Conditions
- Bladder Cancer, Cervical Cancer, Esthesioneuroblastoma, Glioblastoma Multiforme, Large Cell Neuroendocrine Carcinoma of the Lung, Medullary Thyroid Cancer, Melanoma, Merkel Cell Carcinoma, Non Small Cell Lung Cancer, Sinonasal Undifferentiated Carcinoma, Testicular Cancer
- Interventions
- Concurrent Radiation Therapy, Sequential Radiation therapy, Tarlatamab
- Radiation · Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Seattle, Washington
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Interventions
- Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, Ubamatamab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- PTM-101
- Drug
- Lead sponsor
- PanTher Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Detroit, Michigan • Lake Success, New York + 3 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Enzalutamide, PF-06821497, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 44
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 29 more
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Cyclophosphamide, Methotrexate (MTX), Mycophenolate mofetil (MMF), Ruxolitinib (Rux), Tacrolimus (Tac)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 30
- States / cities
- Palo Alto, California • San Francisco, California • Miami, Florida + 23 more
- Conditions
- Large B-cell Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™, cemacabtagene ansegedleucel
- Drug · Device · Genetic
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 58
- States / cities
- Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 47 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration
- Procedure · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 230
- States / cities
- Jonesboro, Arkansas • Beverly Hills, California • Loma Linda, California + 186 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 219
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 175 more